CIP2A expression is increased in prostate cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Vaarala MH;Vaarala MH; Väisänen MR; Ristimäki A
  • Source:
    Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2010 Oct 21; Vol. 29, pp. 136. Date of Electronic Publication: 2010 Oct 21.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2009- : London : BioMed Central
      Original Publication: [Roma] : APSIT,
    • Subject Terms:
      Autoantigens/*analysis ; Membrane Proteins/*analysis ; Prostatic Hyperplasia/*metabolism ; Prostatic Neoplasms/*chemistry; Cell Differentiation ; Finland ; Humans ; Immunohistochemistry ; Intracellular Signaling Peptides and Proteins ; Male ; Neoplasm Staging ; Prostate-Specific Antigen/blood ; Prostatectomy ; Prostatic Hyperplasia/pathology ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Risk Assessment ; Up-Regulation
    • Abstract:
      Background: The CIP2A protein is a recently characterized oncoprotein which inhibits protein phosphatase 2A activity. Expression of CIP2A has been detected in several carcinomas, but its expression and significance in prostate cancer has not been examined so far.
      Methods: Expression of the CIP2A protein was studied using immunohistochemistry in prostate cancer (n = 59) and in benign prostatic hyperplasia (n = 20) specimens. The CIP2A staining scores were compared with several clinicopathological parameters.
      Results: Expression of CIP2A was increased in prostate cancer epithelium as compared with the benign hyperplastic epithelium (p < 0.001). The expression of CIP2A was associated with high Gleason scores (p < 0.001) and among patients treated with radical prostatectomy, CIP2A expression was associated with pre-treatment risk stratification (p = 0.011) and pathological T-class (p = 0.031). No statistically significant association was detected between CIP2A expression and prostate specific antigen concentrations.
      Conclusions: Expression of the CIP2A protein is increased in prostate cancer specimens and its expression is associated with poorly differentiated and high-risk tumors.
    • References:
      Oncogene. 2002 Jul 25;21(32):5006-15. (PMID: 12118381)
      Clin Cancer Res. 2009 Aug 15;15(16):5092-100. (PMID: 19671842)
      Biochim Biophys Acta. 2009 Jan;1795(1):1-15. (PMID: 18588945)
      Clin Cancer Res. 2008 Jun 15;14(12):3722-8. (PMID: 18559589)
      J Med Microbiol. 2010 Mar;59(Pt 3):259-265. (PMID: 19959630)
      Cell. 2007 Jul 13;130(1):51-62. (PMID: 17632056)
      Ann Oncol. 2007 Nov;18(11):1765-73. (PMID: 17426060)
      J Clin Oncol. 2003 Jun 1;21(11):2163-72. (PMID: 12775742)
      J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. (PMID: 19470954)
      Prostate. 2005 May 15;63(3):252-8. (PMID: 15538718)
      Nat Rev Cancer. 2001 Oct;1(1):34-45. (PMID: 11900250)
    • Accession Number:
      0 (Autoantigens)
      0 (CIP2A protein, human)
      0 (Intracellular Signaling Peptides and Proteins)
      0 (Membrane Proteins)
      EC 3.4.21.77 (Prostate-Specific Antigen)
    • Publication Date:
      Date Created: 20101023 Date Completed: 20101228 Latest Revision: 20211020
    • Publication Date:
      20240829
    • Accession Number:
      PMC2984408
    • Accession Number:
      10.1186/1756-9966-29-136
    • Accession Number:
      20964854